Payment overview · 2025
General Payments
$370.32
16 reported records · 11 companies
Healthcare provider profile · identity verified
Angela Inez Payne, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · STARKVILLE, MS · NPI 1740630821
Verified facts
What the public records show
CMS Open Payments records show Angela Inez Payne, M.D. received $370.32 in general payments during 2025 across 16 reported records.
Novo Nordisk Inc accounted for 24.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $88.96 | 24.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $83.20 | 22.5% | 3 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $51.56 | 13.9% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.31 | 6.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.64 | 5.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.02 | 5.1% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $18.02 | 4.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.50 | 4.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.89 | 4.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.84 | 4.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.38 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $370.32 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $83.20 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $83.20 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $83.20 | 3 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $51.56 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.88 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.08 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.08 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $25.31 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 38 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 63 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
102 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
38 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
37 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 580 | 176 |
| Amlodipine Besylate | Amlodipine Besylate | 375 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 352 | 75 |
| Omeprazole | Omeprazole | 313 | 85 |
| Hydrochlorothiazide | Hydrochlorothiazide | 268 | 78 |
| Metformin Hcl | Metformin Hcl | 261 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 251 | 64 |
| Lisinopril | Lisinopril | 243 | 66 |
| Famotidine | Famotidine | 230 | 66 |
| Gabapentin | Gabapentin | 214 | 60 |
| Losartan Potassium | Losartan Potassium | 180 | 45 |
| Meloxicam | Meloxicam | 170 | 57 |
| Furosemide | Furosemide | 169 | 47 |
| Trazodone Hcl | Trazodone Hcl | 168 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 46 |
| Simvastatin | Simvastatin | 135 | 35 |
| Potassium Chloride | Potassium Chloride | 116 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 32 |
| Benztropine Mesylate | Benztropine Mesylate | 107 | 19 |
| Farxiga | Dapagliflozin Propanediol | 102 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 96 | 74 |
| Olanzapine | Olanzapine | 96 | 13 |
| Sertraline Hcl | Sertraline Hcl | 94 | 25 |
| Levetiracetam | Levetiracetam | 93 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 90 | 19 |
| Azithromycin | Azithromycin | 84 | 70 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 24 |
| Montelukast Sodium | Montelukast Sodium | 80 | 27 |
| Ezetimibe | Ezetimibe | 79 | 30 |
| Risperidone | Risperidone | 79 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 19 |
| Memantine Hcl | Memantine Hcl | 77 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 25 |
| Carvedilol | Carvedilol | 75 | 24 |
| Divalproex Sodium | Divalproex Sodium | 74 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 37 |
| Allopurinol | Allopurinol | 71 | 22 |
| Donepezil Hcl | Donepezil Hcl | 68 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 20 |
| Glimepiride | Glimepiride | 66 | 22 |
| Januvia | Sitagliptin Phosphate | 64 | 13 |
| Jardiance | Empagliflozin | 63 | 16 |
| Mirtazapine | Mirtazapine | 63 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 20 |
| Divalproex Sodium Er | Divalproex Sodium | 62 | suppressed |
| Aripiprazole | Aripiprazole | 60 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 19 |
| Buspirone Hcl | Buspirone Hcl | 56 | 15 |
| Ozempic | Semaglutide | 56 | 11 |
| Mupirocin | Mupirocin | 55 | 38 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 55 | 45 |
| Doxazosin Mesylate | Doxazosin Mesylate | 54 | 17 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 51 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 50 | 18 |
| Haloperidol | Haloperidol | 49 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 17 |
| Atenolol | Atenolol | 45 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 38 |
| Finasteride | Finasteride | 43 | suppressed |
| Alprazolam | Alprazolam | 41 | suppressed |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Prednisone | Prednisone | 40 | 21 |
| Linzess | Linaclotide | 39 | 12 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 38 | 38 |
| Lamotrigine | Lamotrigine | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | 15 |
| Eliquis | Apixaban | 37 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Lacosamide | Lacosamide | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 32 |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Lactulose | Lactulose | 34 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 26 |
| Topiramate | Topiramate | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Valsartan | Valsartan | 29 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 28 | 11 |
| Fluconazole | Fluconazole | 28 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 11 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | 12 |
| Lithium Carbonate | Lithium Carbonate | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 21 |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 23 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 13 |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Nystatin | Nystatin | 16 | 13 |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Fycompa | Perampanel | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 11 |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Clozapine | Clozapine | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $370.32 · 16 records | Novo Nordisk Inc | ABRYSVO, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, EVENITY, Flector, JARDIANCE, Kerendia, Licart, Ozempic, PREVNAR 20, QUTENZA, Rybelsus, Tirosint, WATCHMAN Access System, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error